PT - JOURNAL ARTICLE AU - Katharina Röltgen AU - Oliver F. Wirz AU - Bryan A. Stevens AU - Abigail E. Powell AU - Catherine A. Hogan AU - Javaria Najeeb AU - Molly Hunter AU - Malaya K. Sahoo AU - ChunHong Huang AU - Fumiko Yamamoto AU - Justin Manalac AU - Ana R. Otrelo-Cardoso AU - Tho D. Pham AU - Arjun Rustagi AU - Angela J. Rogers AU - Nigam H. Shah AU - Catherine A. Blish AU - Jennifer R. Cochran AU - Kari C. Nadeau AU - Theodore S. Jardetzky AU - James L. Zehnder AU - Taia T. Wang AU - Peter S. Kim AU - Saurabh Gombar AU - Robert Tibshiran AU - Benjamin A. Pinsky AU - Scott D. Boyd TI - SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness AID - 10.1101/2020.08.15.20175794 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.15.20175794 4099 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175794.short 4100 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175794.full AB - SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected outpatients and asymptomatic individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. The development of plasma antibodies was correlated with decreases in viral RNAemia, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA, we detected antibodies blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies recognizing SARS-CoV RBD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic individuals’ serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study and authors were supported by NIH/NIAID R01AI127877, NIH/NIAID R01AI130398, and an endowment to SDB from the Crown Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Stanford University Institutional Review Board (protocol # 48973).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials.